Oncology The gut microbiome: the next breakthrough in cancer? Ben Hargreaves discovers how research has emerged outlining how the gut microbiome plays a crucial role in patients’ response to cancer treatments.
R&D Allogeneic therapies: The future of cancer treatment? Allogeneic therapies could provide an answer to some of the drawbacks of autologous therapies.
Oncology World Thrombosis Day at 10, talking blood clots and cancer A new 'Move Against Thrombosis' campaign and discussion of cancer-related blood clotting.
Oncology Better balance of cancer treatment efficacy and toxicity The FDA Oncology Center of Excellence announced its Project Optimus draft guidance in January.
Oncology Pfizer’s bispecific elranatamab and future oncological care Pfizer announced that the FDA granted Priority Review for its BLA for bispecific elranatamab.
Oncology Time to level the playing field for men with prostate cancer Prostate cancer affects not just patients, but their families too.
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.